Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics reports developments tied to its oncology drug-development portfolio and corporate transition. The company had developed novel oncology therapies including ONCT-534, a dual-action androgen receptor inhibitor for relapsed or refractory metastatic castration-resistant prostate cancer; ONCT-808, an autologous ROR1-targeting CAR T therapy for aggressive B-cell lymphoma; and zilovertamab, an investigational ROR1 monoclonal antibody.
Recurring news themes include clinical-study updates, safety and efficacy data, financial results, termination of clinical programs, strategic-alternative activity, asset sales and the wind-down of operations.
Oncternal Therapeutics, a clinical-stage biopharmaceutical company, provided a business update and reported first quarter 2024 financial results. The company is progressing well with its Phase 1/2 studies for ONCT-534 and ONCT-808, focusing on prostate cancer and B-cell lymphoma, respectively. They also announced a cash balance of $27.0 million as of March 31, 2024, which is projected to fund operations until Q1 2025.
Oncternal Therapeutics, a clinical-stage biopharmaceutical company, will report its first quarter 2024 financial results on May 9, 2024. The company focuses on developing novel oncology therapies and will host a webcast to discuss the results and provide a business update.
Oncternal Therapeutics, a clinical-stage biopharmaceutical company, granted an inducement award to a new Senior Director, Clinical Data Management, Anne C. Hansen. The award includes an option to purchase 5,000 shares of Oncternal common stock, with a 10-year term and vesting over four years. The approval was made under the company's 2021 Employment Inducement Incentive Award Plan, following Nasdaq Rule 5635(c)(4).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.